[go: up one dir, main page]

MX2018001205A - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h. - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h.

Info

Publication number
MX2018001205A
MX2018001205A MX2018001205A MX2018001205A MX2018001205A MX 2018001205 A MX2018001205 A MX 2018001205A MX 2018001205 A MX2018001205 A MX 2018001205A MX 2018001205 A MX2018001205 A MX 2018001205A MX 2018001205 A MX2018001205 A MX 2018001205A
Authority
MX
Mexico
Prior art keywords
inhibitor
isocitrate dehydrogenase
adduct
idh1
mutated isocitrate
Prior art date
Application number
MX2018001205A
Other languages
English (en)
Inventor
Schirmer Heiko
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2018001205A publication Critical patent/MX2018001205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al ácido aductivo (2E)-but-2-enedioico y ácido 3-(2-{[4-(trifluorometoxi)fenil]amino }-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-benzimidazol-5-il)propa noico (1:4), a métodos para preparar este aducto, composiciones que comprenden este aducto y, también al uso de este aducto para preparar un medicamento para el tratamiento de una enfermedad.
MX2018001205A 2015-07-27 2016-07-22 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h. MX2018001205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27
PCT/EP2016/067477 WO2017016992A1 (en) 2015-07-27 2016-07-22 Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h

Publications (1)

Publication Number Publication Date
MX2018001205A true MX2018001205A (es) 2018-04-24

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001205A MX2018001205A (es) 2015-07-27 2016-07-22 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h.

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6534675B2 (ja) 2014-02-11 2019-06-26 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
CN107108554B (zh) 2014-10-23 2020-11-06 德国癌症研究中心 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
CN107810176B (zh) 2015-06-08 2020-10-16 德国癌症研究公共权益基金会 作为mIDH1抑制剂的N-薄荷基苯并咪唑类化合物
WO2017005674A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
US10414734B2 (en) 2015-07-16 2019-09-17 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
CN111278465A (zh) * 2017-08-01 2020-06-12 德国癌症研究中心 mIDH1抑制剂和DNA低甲基化剂（HMA）的组合
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
AU2021311539A1 (en) 2020-07-21 2023-02-09 Daiichi Sankyo Company, Limited Combination drug of temozolomide and inhibitor of mutated IDH1 enzyme

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151441A1 (en) 2009-06-23 2010-12-29 Translational Genomics Research Institute Benzamide derivatives
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP6534675B2 (ja) 2014-02-11 2019-06-26 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
US9951027B2 (en) * 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
ES2822654T3 (es) * 2014-10-23 2021-05-04 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Benzimidazol-2-aminas como inhibidores de mIDH1
CN107108554B (zh) * 2014-10-23 2020-11-06 德国癌症研究中心 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
CN107810176B (zh) 2015-06-08 2020-10-16 德国癌症研究公共权益基金会 作为mIDH1抑制剂的N-薄荷基苯并咪唑类化合物
WO2017005674A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
US10414734B2 (en) * 2015-07-16 2019-09-17 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
EP3121166A1 (en) * 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) * 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
KR20180030789A (ko) 2018-03-26
US10344004B2 (en) 2019-07-09
EA201890386A1 (ru) 2018-08-31
CU20180014A7 (es) 2018-06-05
TN2018000038A1 (en) 2019-07-08
HK1252449A1 (zh) 2019-05-24
EP3328837A1 (en) 2018-06-06
JP6804516B2 (ja) 2020-12-23
CR20180053A (es) 2018-03-20
US20180222870A1 (en) 2018-08-09
IL256024A (en) 2018-01-31
CO2018000793A2 (es) 2018-05-10
BR112018001534A2 (pt) 2018-09-11
DOP2018000027A (es) 2018-02-28
ES2860693T3 (es) 2021-10-05
WO2017016992A1 (en) 2017-02-02
CN107810181B (zh) 2021-06-22
NI201800014A (es) 2018-09-06
JP2018521095A (ja) 2018-08-02
EP3328837B1 (en) 2021-01-06
CN107810181A (zh) 2018-03-16
CA2993473A1 (en) 2017-02-02
TW201708193A (zh) 2017-03-01
PE20181038A1 (es) 2018-07-03
ECSP18006465A (es) 2018-04-30
SV2018005621A (es) 2018-12-05
AU2016300980B2 (en) 2020-12-24
CL2018000249A1 (es) 2018-07-06
AR105493A1 (es) 2017-10-11
AU2016300980A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
MX2018001205A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h.
WO2015101958A3 (en) Inhibitors of glutaminase
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
ZA201606320B (en) Human plasma kallikrein inhibitors
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
NZ721298A (en) Pharmaceutical compositions comprising azd9291
TW201613903A (en) Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
HK1245100A1 (zh) 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
PH12016501462A1 (en) Neprilysin inhibitors
NZ721645A (en) Compounds for use as gpr120 agonists
MX2018001204A (es) Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil- 1h-bencimidazol-5-il)propanoico sustituido.
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
MX375468B (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека
HK1231074A1 (en) Neprilysin inhibitors
HK1230104A1 (en) Methods and compositions for the treatment of vascular malformation